Doctors often reach a stalemate when they manage B cell-driven autoimmune diseases (AIDs). Standard therapies like steroids and rituximab frequently fail to provide durable relief for these patients. These traditional treatments result in incomplete responses. Because they do not achieve a total reset of the immune system, the patient eventually relapses. However, recent progress in cellular engineering has introduced CD19 CAR-T cell therapy. This is a potent intervention for refractory cases. Unlike conventional biologics, CAR-T cells offer a more profound depletion of the B cell lineage. The source of pathogenic autoantibodies can be eradicated by this method.

A case report was published in the journal Med recently. It details a significant breakthrough in the field. Three separate autoimmune conditions was treated at the same time in one single patient. These conditions were autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), and antiphospholipid syndrome (APLAS). Zorpo-cel was the therapy used for this. This triple victory represents a paradigm shift in medical literature. It suggest that complex, multi-morbid profiles can be resolved by a single targeted cellular intervention. For this specific patient, 9 prior lines of therapy had failed before the CAR-T treatment was finally started. This result was achieved with 1 infusion.

The B Cell Reset Methodology

The scientific logic of this treatment is based on the B cell reset concept. In diseases like AIHA, ITP, and APLAS, dysregulated B cells produce autoantibodies. These antibodies target red blood cells, platelets, and phospholipids. Zorpo-cel (zorpocabtagene-autoleucel) is the specific CAR-T cell product used here. It is an autologous, 4-1BB-costimulated product. It was manufactured using the Miltenyi Prodigy platform. These engineered T cells seek out and destroy the B cell population by targeting the CD19 antigen. This antigen is expressed on the surface of most B cells.Send Inquiry

Contact Us For Best Would you Like to Know more We can Give you the answer, For inquiries about our products and services. please leave your e-mail to us and will reply within 24 hours.

Click for inquiryThe patient was a 47-year-old woman. A lymphodepletion regimne of fludarabine and cyclophosphamide was administered first. After this, she received a single infusion of 106 Zorpo-cel units per kg of body weight. The methodology aims to create a “tabula rasa” for the immune system. Once the CAR-T cells clear the pathogenic B cells and leave the circulation, the system can regenerate. A healthy, naive B cell population is created that lacks the original dysregulation. Zorpo-cel is different from rituximab because it has deeper tissue penetration. Rituximab often fails to eradicate B cells in lymphoid tissues or mucosal areas, but this cellular therapy is more affective.

Clinical Markers and Treatment Timeline

The report provides a comprehensive overview of the patient’s clinical trajectory, illustrating the failure of traditional methods and the subsequent success of Zorpo-cel.

Exhaustive Prior Treatment History

Fig 1 Clinical course from diagnosis to CAR-T infusion, including thromboembolic events and APLA titers

Fig 1 maps the patient’s ten-year struggle with multi-refractory disease. She began treatment in 2014. Doctors used steroids and rituximab three separate times. High-dose intravenous immunoglobulins (IVIGs) were also administered. Other immunosuppressants like mycophenolate mofetil and bortezomib were tried too. The patient still suffered frequent AIHA flares and ITP relapses. Thromboembolic events related to APLAS occured despite these efforts. This section of the figure shows why a more aggressive cellular intervention was necessary.

Rapid Normalization of Hemoglobin

Fig 2 Post-CAR-T changes in LDH, hemoglobin, and red blood cell transfusions

Fig 2 tracks the resolution of hemolysis after the CAR-T infusion. The change was quite dramatic. Before this treatment, the patient was transfusion-dependent. She required up to three red blood cell concentrates daily. Lactate dehydrogenase (LDH) is a marker of cell destruction and it was severely elevated at 4,601 U/L. Transfusion independence was achieved by Day 7 following Zorpo-cel administration. Hemoglobin (Hb) levels normalized to 13.0 g/dL by Day 25. At the same time, LDH levels dropped to normal ranges by Day 29. This signaled the cessation of active hemolysis.

Platelet and Inflammation Dynamics

Fig 3 Platelet counts after CAR-T infusion and ferritin/CRP levels before and after therapyFig 3 highlight the secondary clinical benefits and systemic responses. Platelets were critically low during ITP flares but they stabilized later. The count increased to 70/nL without further ITP-specific therapy. Ferritin and C-reactive protein (CRP) levels peaked around the time of the AIHA flare. Lymphodepletion also contributed to this peak. CRP normalized within 29 days. The sustained elevation of ferritin shown in Fig 3D was attributed to iron overload. This was caused by years of transfusions. Phlebotomy was eventually required to treat the iron levels.

Kinetics of Cellular Reset

Fig 4 Kinetics of CD3+ CAR-T cells and B cells post-infusion, and B cell phenotype at day 322Fig 4 illustrate the mechanism of action at a cellular level. CAR-T cells expanded rapidly and peaked at 10.5 cells/µl on Day 9. This expansion coincided with the total depletion of circulating B cells. B cells finally recurred at Day 322. They exhibited a naive phenotype of 98%. This confirms that the dysregulated clones were successfully replaced. The new B cell population was healthy and did not produce the same autoantibodies. The occurance of naive cells suggests a successful immune system reset.

Antibody Abrogation and Safety Profile

Next, it focuses on the serological evidence of remission and the safety profile of the therapy.

Resolution of Pathogenic Autoantibodies

Fig 5 Direct Coombs test results from fresh blood over timeThe direct Coombs test (Fig 5) measures the presence of antibodies on red blood cells. Before CAR-T therapy, the patient tested at the highest possible positivity (++++), indicating severe AIHA. Following the B cell reset, this titer decreased gradually, eventually reaching low or absent levels. This provides direct evidence that the source of the hemolytic antibodies was eliminated.

Normalization of Antiphospholipid Markers

Fig 6 Antiphospholipid antibody (APLA) titers measured from frozen serum samples

Fig 6 is notable because it shows the abrogation of APLAS markers. Anti-cardiolipin (IgG and IgM) and anti-glycoprotein antibodies were high. These levels were well above the normal range of < 12 U/mL. The markers normalized rapidly following Zorpo-cel infusion. They remained negative throughout the 11-month follow-up. This result allowed the patient to reduce and eventually stop anticoagulation therapy. No new thromboembolic events was observed after the treatment stopped.

Hematological and Liver Toxicity

Fig 7 Clinical course from diagnosis to CAR-T infusion, including thromboembolic events and APLA titers

Fig 7 tracks the safety and adverse events. The patient experienced Grade 4 lymphocytopenia. This is a expected result after lymphodepleting chemotherapy. The therapy was administered without any signs of Cytokine Release Syndrome (CRS). No neurotoxicity (ICANS) was observed in the patient. These are common risks in oncological CAR-T applications. A transient rise in liver enzymes (ALAT/GPT) was observed in Fig 7D. However, this was attributed to drug-induced injury or pre-existing iron overload. The CAR-T cells themselves did not seem to cause the rise.

Conclusion

This case study demonstrates that CD19 CAR-T cell therapy can induce rapid, treatment-free remission in patients with multiple, overlapping autoimmune diseases. By achieving a deep B cell reset, Zorpo-cel addressed the root cause of AIHA, ITP, and APLAS simultaneously, restoring the patient’s physical strength and quality of life. While further controlled clinical trials are necessary to confirm these findings across larger populations, the “triple victory” seen here offers a compelling logic for the use of cellular therapies in the most challenging refractory cases. For clinicians and patients facing the limits of traditional medicine, Zorpo-cel provides a transformative path toward sustained, drug-free remission.This case report demonstrates that a single infusion of CD19 CAR-T cells (Zorpo-cel) can achieve simultaneous, drug-free remission of three refractory autoimmune diseases by resetting the B cell compartment, offering a transformative paradigm for cellular immunotherapy. Alpha Lifetech offers specialized CRO services in Phage Display-based Antibody Discovery – including VHH, Fab, scFv, Aptamer, and Peptide development – to help you translate cutting-edge genomic insights into precise biologic therapeutics.

Media Contact
Company Name: Alpha Lifetech Incorporation
Email: Send Email
Phone: +1 609-736-0910
Address:90 State Street, STE 700 Office 40
City: Albany
State: NY 12207
Country: China
Website: https://www.alpha-lifetech.com/